Top 5 Analyst Questions From Lucky Core Industries (LCI) Corporate Briefing

Lucky Core Industries (LCI) held its corporate briefing on February 10. Here are the top 5 questions asked by analysts during the LCI corporate briefing.

The Pfizer Acquisition and Portfolio Transformation

Asked by: Muhammad Abrar (Arif Habib Limited) & Topline Securities

📢 Announcement: You can now access our services and similar analyses by opening an account with us via JS Global

How quickly will the PKR 5 billion Pfizer acquisition become the primary driver of the Pharmaceutical segment, and what is the current status of the manufacturing transition?

Asif Jooma (Chief Executive):

“The integration of iconic brands like Ponstan, Mucaine, and Lysovit has fundamentally shifted our portfolio towards 75% non-essential products, giving us significantly more pricing agility and resilience against regulatory caps.”

Defending Market Share in Soda Ash

📢 Announcement: We're on WhatsApp – Join Us There! 

Asked by: Insight Securities & JS Global

With domestic demand falling by 18%, how does LCI plan to maintain its 65% market share against the rising threat of cheaper imported Soda Ash?

Muhammad Umar Mushtaq (COO Soda Ash):

“Our focus is on cost leadership. By optimizing our fuel mix through the newly commissioned multi-fuel alternate energy boiler at Khewra, we can absorb pricing pressure from imports while keeping our domestic margins sustainable.”

Timelines for Major Capacity Expansions

Asked by: Taurus Securities

Can management provide a definitive timeline for the 200,000-ton Soda Ash expansion, and what is the projected Capex for the coming year?

Atif Aboobukar (CFO):

“We are in a disciplined design and engineering phase for the 200k expansion, which will last approximately one year. We are being cautious with capital; larger projects will be triggered based on market demand recovery and interest rate trajectories.”

Strategic Pivot in Animal Health & Agri Sciences

Asked by: Chase Securities

Given the 10% decline in Animal Health sales, what structural changes are being implemented to return this segment to a growth trajectory?

Nauman Shahid Afzal (COO Chemicals & Agri Sciences):

“We have made the strategic decision to discontinue the low-margin silage portfolio. Our focus has shifted entirely to high-margin veterinary medicines, supported by our new PKR 725 million greenfield facility slated for FY26.”

Navigating the Textile Slump in Polyester

Asked by: Intermarket Securities (IMS) & Arif Habib Limited

With a 7% drop in Polyester volumes, is this a permanent shift in demand, and how is the company managing the volatile PTA and MEG margin spread?

Rizwan Afzal Chaudhry (COO Polyester):

“We are navigating a difficult domestic textile environment by focusing on effective margin management rather than chasing low-margin volume. We are maintaining lean inventories and focusing on specialized fiber variants.”

⚠️ This post reflects the author’s personal opinion and is for informational purposes only. It does not constitute financial advice. Investing involves risk and should be done independently. Read full disclaimer →